A Saven, KA Foon, LD Piro - Annals of internal medicine, 1994 - Am Coll Physicians Langerhans-cell histiocytosis results from the proliferation and accumulation of
tissue histiocytes, clinically manifested as osteolytic lesions, hypothalamic
insufficiency, and seborrheic and vesiculopustular lesions on the scalp, ... Cited by 43 - Related articles - All 5 versions
KC Stine, RL Saylors, LL Williams, DL Becton - Pediatric Blood & Cancer - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 31 - Related articles - BL Direct - All 3 versions
S Weitzman, AS Wayne, R Arceci, JM Lipton, … - Medical and pediatric oncology, 1999 - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 41 - Related articles - BL Direct - All 3 versions
MA Dimopoulos, M Theodorakis, E Kostis, C … - Leukemia & lymphoma, 1997 - informahealthcare.com Page 1. Leukemia and Lyniphoma, Vol. 25, pp. 187-189 Reprints available directly
from the publisher Photocopying permitted by license only ... Cited by 14 - Related articles - BL Direct - All 5 versions
C Rodriguez-Galindo, P Kelly, M Jeng, GG … - American journal of hematology, 2002 - interscience.wiley.com Langerhans cell histiocytosis (LCH) is a disorder characterized by proliferation
of activated Langerhans cells. Immune dysregulation is believed to be part of
the pathogenesis. Although current therapies are very effective at inducing ... Cited by 30 - Related articles - BL Direct - All 3 versions
- ►hematologylibrary.org A Saven, C Burian - Blood, 1999 - bloodjournal.hematologylibrary.org Langerhans-cell histiocytosis (LCH) results from the accumulation of tissue
histiocytes derived from the same progenitor cells as monocytes. Because
cladribine is potently toxic to monocytes, we conducted a phase II trial of ... Cited by 56 - Related articles - BL Direct - All 6 versions
A Saven, ML Figueroa, LD Piro, JD … - The New England Journal of Medicine, 1993 - nejm.highwire.org Four courses of 2-chlorodeoxyadenosine (0.1 mg per kilogram of body weight per
day for 7 days by continuous intravenous infusion) were administered every 28 to
35 days. The second course was delayed by the development of dermatomal ... Cited by 34 - Related articles - All 4 versions
RE Brown - Medical and pediatric oncology, 2001 - cat.inist.fr Position paper: bisphosphonates as antialveolar macrophage therapy in pulmonary
langerhans cell histiocytosis? Robert E BROWN Medical ... Cited by 11 - Related articles - BL Direct - All 4 versions
A Pardanani, RL Phyliky, CY Li, A Tefferi - Mayo Clinic Proceedings, 2003 - mayoclinicproceedings.com From the Division of Hematology and Internal Medicine (AP, RLP, AT) and Division
of Hematopathology (C.-YL), Mayo Clinic, Roch- ester, Minn. Address reprint
requests and correspondence to Ayalew Tefferi, MD, Division of Hematology, ... Cited by 37 - Related articles - View as HTML - BL Direct - All 9 versions
F Bernard, C Thomas, Y Bertrand, M Munzer, … - European Journal of Cancer, 2005 - Elsevier The aim of this study was to assess the efficacy and adverse effects of
2-chlorodeoxyadenosine (2-CdA) and cytosine arabinoside (Ara-C) in children with
refractory Langerhans cell histiocytosis (LCH) and haematopoietic ... Cited by 30 - Related articles - All 24 versions
